<DOC>
	<DOCNO>NCT00804934</DOCNO>
	<brief_summary>The purpose study determine whether people receive intermittent anti-VEGF therapy improvement vision switch monthly injection Lucentis .</brief_summary>
	<brief_title>Investigates Improvement Vision Following Switching From Avastin Macugen Over Lucentis</brief_title>
	<detailed_description>To determine mean change visual acuity 6 12 month</detailed_description>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age great equal 50 year Patients active neovascular AMD Received least 3 treatment antiVEGF therapy ( bevacizumab pegaptanib ranibizumab ) last 24 month If patient bilateral disease qualifies study , eye may include Subjects meet follow criterion exclude study : Pregnancy lactation Premenopausal woman use adequate contraception . Participation another simultaneous medical investigation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>